Pharmaceutical Sales: 100% (2026)

Top 3 Markets:

1. India: approximately 90%
2. Southeast Asia: approximately 5%
3. Africa: approximately 3%

Eris Lifesciences Limited generates the majority of its sales from the pharmaceutical industry, with the Indian market accounting for the largest share. The company is heavily involved in the prescription drug sector, particularly in the segments of diabetes, cardiovascular diseases, and gastroenterology.

The Indian market is the main revenue driver, attributed to its strong presence and targeted market development in this area. The company's expansion into international markets such as Southeast Asia and Africa demonstrates its commitment to expanding its global reach and seizing new growth opportunities.

Production Sites: Ahmedabad, Gujarat, India

Eris Lifesciences Limited primarily produces its pharmaceutical products in Ahmedabad, Gujarat. This production facility specializes in formulation manufacturing and plays a central role in the company's supply chain.

The company places great emphasis on quality and compliance, which is why the production facilities adhere to strict regulatory standards. Due to its strategic location in India, Eris Lifesciences can efficiently serve both the domestic and international markets.

Revenue Growth: 10% (estimated for 2026)

Focus on Research and Development: Eris Lifesciences is increasing its investment in research and development to bring innovative products to the market. This includes both expanding the existing product portfolio and developing new medications.

Market Expansion: The company plans to expand its presence in new geographical markets, especially in emerging countries, to benefit from the increasing demand for healthcare products.

Strategic Acquisitions: Eris Lifesciences pursues a strategy of strategic acquisitions to strengthen its market position and integrate new technologies and expertise.

These strategies are intended to secure the company's long-term growth and enhance its competitiveness in the global market.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients

Countries of origin: China, India, Europe

Eris Lifesciences Limited mainly imports active pharmaceutical ingredients (APIs) and excipients needed for the production of their medicines. A significant portion of these raw materials is sourced from China, as the country is one of the largest producers of APIs worldwide.

Additionally, raw materials are also imported from European countries to meet quality standards and ensure diversification of supply chains. India itself is also a significant producer of pharmaceutical raw materials, and Eris Lifesciences could also use locally sourced materials to optimize costs and shorten lead times.

Dependency on imports, especially from China, is a common pattern in the pharmaceutical industry due to the well-established infrastructure for API manufacturing there.

Market share: 3.5% in the Indian pharmaceutical market (2025)

Revenue growth: 10% (2025)

EBITDA margin: 32% (2025)

Eris Lifesciences Limited has established itself as a significant player in the Indian pharmaceutical market, especially in the cardiovascular and diabetology medication sector. With a market share of 3.5%, the company holds a solid position supported by its strong brand presence and diversified product portfolio.

The 10% revenue growth in 2025 demonstrates that Eris Lifesciences is capable of further expanding its market position, attributed to an effective distribution strategy and successful product launches. The high EBITDA margin of 32% indicates an efficient cost structure and strong pricing power, providing the company with a significant competitive advantage.

Additionally, Eris benefits from a strong focus on the Indian market, enabling it to quickly respond to local market trends and regulatory changes. Continuous investment in research and development further supports the company's innovation capabilities and strengthens its competitiveness.

Institutional Investor Share: approximately 25% (2026, estimated)

Insider Buys/Sells: No significant transactions in the last year

The institutional investor share in Eris Lifesciences Limited is estimated to be around 25%. This figure reflects the confidence of institutional investors in the company, which is often seen as a positive signal for the company's stability and growth potential.

Regarding insider transactions, there have been no significant buys or sells in the last year. This could indicate that insiders are satisfied with the current valuation of the company or do not expect immediate changes in the company's value.

Market share of Eris Lifesciences Limited: 3.5% (estimated, 2026)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 8.2%
2. Cipla Ltd.: 7.5%
3. Dr. Reddy's Laboratories Ltd.: 6.9%
4. Aurobindo Pharma Ltd.: 5.8%
5. Lupin Ltd.: 5.2%
6. Zydus Cadila: 4.7%
7. Torrent Pharmaceuticals Ltd.: 4.1%
8. Glenmark Pharmaceuticals Ltd.: 3.9%
9. Alkem Laboratories Ltd.: 3.6%
10. Eris Lifesciences Ltd.: 3.5%

Moat of Eris Lifesciences:

Eris Lifesciences has specialized in the Indian market with a focus on lifestyle and chronic diseases, which represents a certain moat. Their advantage lies in a strong presence in the prescription drugs sector and the ability to build close relationships with doctors and medical professionals.

However, compared to larger competitors like Sun Pharmaceutical and Cipla, which have more extensive product portfolios and international presence, Eris's moat is less pronounced. These companies benefit from economies of scale and broader geographic diversification, giving them a stronger competitive advantage.

Eris Lifesciences could strengthen its moat through investments in research and development as well as strategic partnerships to differentiate itself from the competition.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) Research & Development Expenses: 6% of revenue (2025)

Eris Lifesciences Limited recorded a solid revenue growth of 10.5% in 2025, attributed to a strong product pipeline and successful market launches. The profit growth of 8.2% indicates that the company is able to increase its profitability despite rising costs.

The company continuously invests in research and development, with 6% of revenue allocated to this area. This suggests a strategic focus on innovation and long-term growth.

In summary, Eris Lifesciences Limited could be an attractive investment opportunity due to its solid financial performance and investments in future growth. However, investors should also consider external factors such as regulatory changes and market conditions.

Dividend Yield: 1.5% (estimated for 2026)

Eris Lifesciences Limited has regularly paid out dividends in the past. The dividend yield has remained stable at around 1.5% in recent years. This demonstrates a certain reliability in the company's dividend distribution policy.

The company has a solid financial foundation and a consistent earning power, indicating that it should also be able to pay dividends in the future. Analysts estimate that Eris Lifesciences will continue to pursue a similar dividend policy, unless significant market changes occur.